Treatment of Graves' ophthalmopathy with high-dose intravenous methylprednisolone: a comparison of two dosing regimens

Endocrinologia y Nutricion

Volumn 56, Issue 3, 2009, Pages 118-122

  Sánchez Ortiga, Ruth ^a   Moreno Pérez, Óscar ^a   González Sánchez, Víctor ^a   Arias Mendoza, Nieves ^a   Mauri Dot, Montserrat ^b   Alfayate Guerra, Rocío ^b   López Macia, Alicia ^a   Picó Alfonso, Antonio ^a  

^a Endocrinology Department Alicante General Universitary Hospital Alicante Spain   (Spain)

^b Hormone Laboratory Alicante General Universitary Hospital Alicante Spain   (Spain)

Author keywords

Adverse effects; Graves' disease; Graves' ophthalmopathy; Methylprednisolone; Recurrence

Indexed keywords

METHYLPREDNISOLONE; RADIOACTIVE IODINE;

ADULT; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG MEGADOSE; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; ENDOCRINE OPHTHALMOPATHY; FEMALE; HUMAN; HYPERGLYCEMIA; INTRAHEPATIC CHOLESTASIS; MALE; MULTIPLE CYCLE TREATMENT; NON INSULIN DEPENDENT DIABETES MELLITUS; SIDE EFFECT;

ADULT; AGED; DRUG ADMINISTRATION SCHEDULE; DRUG-INDUCED LIVER INJURY; FEMALE; GRAVES OPHTHALMOPATHY; HASHIMOTO DISEASE; HUMANS; HYPERGLYCEMIA; INFUSIONS, INTRAVENOUS; MALE; METHYLPREDNISOLONE; MIDDLE AGED; PULSE THERAPY, DRUG; RECURRENCE; RETROSPECTIVE STUDIES; TREATMENT OUTCOME;

EID: 65549092030     PISSN: 15750922     EISSN: 15792021     Source Type: Journal    
DOI: 10.1016/S1575-0922(09)70841-1     Document Type: Article

References (11)

1. Marcocci C., Bartalena L., Tanda M.L., Manetti L., Dell'Unto E., Rocchi R., et al. Comparison of the effectiveness and tolerability of intravenous or oral glucocorticoids associated with orbital radiotherapy in the management of severe Graves' ophthalmopathy: results of a prospective, single-blind, randomized study. J Clin Endocrinol Metab 8 (2001) 3562-3567
2. Macchia P.E., Bagattini M., Lupoli G., Vitale M., Vitale G., and Fenzi G. High-dose intravenous corticosteroid therapy for Graves' ophthalmopathy. J Endocrinol Invest 24 (2001) 152-158
3. Kahaly G.J., Pitz S., Hommel G., and Dittmar M. Randomized, single blind trial of intravenous versus oral steroid monotherapy in Graves' orbitopathy. J Clin Endocrinol Metab 90 (2005) 5234-5240
4. Aktaran S., Akarsu E., Erbagci I., Araz M., Okumus S., and Kartal M. Comparison of intravenous methylprednisolone therapy vs. oral methylprednisolone therapy in patients with Graves' ophthalmopathy. Int J Clin Pract 61 (2007) 45-51
5. Van Geest R.J., Sasim I.V., Koppeschaar H.P., Kalmann R., Stravers S.N., Bijlsma W.R., et al. Methylprednisolone pulse therapy for patients with moderately severe Graves' orbitopathy: a prospective, randomized, placebo-controlled study. Eur J Endocrinol 158 (2008) 229-237
6. Bartalena L., Baldeschi L., Dickinson A., Eckstein A., and Kendall-Taylor P. Consensus statement of the European Group on Graves' orbitopathy (EUGOGO) on management of GO. Eur J Endocrinol 158 (2008) 273-285
7. Le Moli R., Baldeschi L., Saeed P., Regensburg N., Mourits M.P., and Wiersinga W.M. Determinants of liver damage associated with intravenous methylprednisolone pulse therapy in Graves' ophthalmopathy. Thyroid 17 (2007) 357-362
8. Weissel M., and Hauff W. Fatal liver failure after high-dose glucocorticoid pulse therapy in a patient with severe thyroid eye disease. Thyroid 10 (2000) 521
9. Marino M., Morabito E., Brunetto M.R., Bartalena L., Pinchera A., and Marocci C. Acute and severe liver damage associated with intravenous glucocorticoid pulse therapy in patients with Graves' ophthalmopathy. Thyroid 14 (2004) 403-406
10. Salvi M., Vannucchi G., Sbrozzi F., Bottari del Castello A., Carnevali A., Fargion S., et al. Onset of autoimmune hepatitis during intravenous steroid therapy for thyroid-associated ophthalmopathy in a patient with Hashimoto's thyroiditis: case report. Thyroid 14 (2004) 631-634
11. Marino M., Morabito E., Altea M.A., Ambrogini E., Olivari F., Brunetto M.R., et al. Autoimmune hepatitis during intravenous glucocorticoid pulse therapy for Graves' ophthalmopathy treated successfully with glucocorticoids themselves. J Endocrinol Invest 28 (2005) 280-284